We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

106 hedge funds and large institutions have $13.5M invested in Sanofi Contingent Value Rights in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 18 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more capital invested

Capital invested by funds: $12.6M → $13.5M (+$914K)

7% less funds holding

Funds holding: 114106 (-8)

22% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 18

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

50% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 16

Holders
106
Holders Change
-8
Holders Change %
-7.02%
% of All Funds
2.82%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
8
Increased
14
Reduced
18
Closed
16
Calls
Puts
Net Calls
Net Calls Change

GCVRZ Hedge Fund Activity: Q1 2016 in Review

106 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q1 2016, worth a combined $13.5M — up 7.2% from $12.6M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of GCVRZ and 8 opened new positions — a net loss of 8 holders — while 18 trimmed existing stakes and 14 added.

The largest buyer was Stonehill Capital Management, adding an estimated $581K. The largest seller was Silverback Asset Management, exiting entirely with an estimated $97K sold.

  • 106 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q1 2016, down from 114 in Q4 2015.
  • Funds reported $13.5M of Sanofi Contingent Value Rights stock for Q1 2016, up 7.2% quarter-over-quarter.
  • 8 funds opened new Sanofi Contingent Value Rights positions in Q1 2016 and 16 closed out, a net change of -8 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q1 2016 was Stonehill Capital Management, an estimated $581K added.
  • The largest Sanofi Contingent Value Rights seller in Q1 2016 was Silverback Asset Management, an estimated $97K sold.

Based on aggregated 13F filings for Q1 2016.